NCT01449409Active, not recruiting
Reduce IDentified UNcontrolled Asthma
Reduce IDentified UNcontrolled Asthma: A Real-time Randomized Administrative Outreach Study to Promote Asthma Guideline Implementation (RIDUNA)
Source: ClinicalTrials.gov · Last updated 5 Aug 2026
Brief summary (registry, in English)
The purpose of Reduce IDentified UNcontrolled Asthma (RIDUNA) is to determine the benefit of real-time identification of uncontrolled asthma by electronic administrative records linked to real-time notification of uncontrolled status to patients and asthma specialists with recommended guideline directed intervention by physicians. The investigators hypothesize that real-time outreach following National guideline asthma care recommendations, after real-time identification of an uncontrolled asthma event in persistent asthmatics on inhaled corticosteroids will lead to better improvements in asthma control (impairment and risk) compared to standard asthma care outreach.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 3000 (estimated)
- First submitted
- 3 Oct 2011
- Start date
- 1 Feb 2011
- Primary completion date
- 31 Dec 2023
- Lead sponsor
- Kaiser Permanente
- Diseases
- Asthma
- NCT number
- NCT01449409
What you commit to
- Study type: Interventional
- Planned participants: 3000
- From 1 Feb 2011 to the primary completion date, 31 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- steroid dependent asthma,
- omalizumab therapy within the past 3 months, and
Other illness
- Patients with chronic obstructive lung disease,
- pulmonary hypertension or other clinically relevant non-asthma pulmonary disorder such as autoimmunity,
- cancer,
- HIV,
Other
- emphysema,
- cystic fibrosis,
- chronic bronchitis,
- bronchiectasis,
- Churg Strauss,
- Wegener's,
- sarcoidosis,
- immune deficiency,
- requirement for an interpreter.
Who the study is looking for
- KPSC members at time of uncontrolled event:
- 12-56 years of age
- Continuously enrolled and with pharmacy benefit for the past year
- Dispensed inhaled corticosteroid (ICS) in the past 6 months.
- Uncontrolled asthma: defined within the past year
- Impairment cohort: 7th short-acting beta-agonist (SABA) canister dispensed and/or
- Risk (exacerbation) cohort: 2nd oral corticosteroid (OCS)dispensing with provider asthma exacerbation encounter within 2 days and at least 1 month after the first OCS dispensing.
Age in the registry: 12 years to 56 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kaiser Permanente Southern California Region Coordinator of this site? Confirm its status | San Diego | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.